Table 2.

Number of days with grade 2 or higher bleeding by age group, overall, and within disease treatment category

Outcome	P for interaction between age group and disease treatment category	0-5 y	6-12 y	13-18 y	≥ 19 y	Total	P for overall comparison of the 4 age groups	Significant pairwise comparisons*
No. of patients		66	69	65	1072	1272
No. of days with bleeding of grade 2 or higher, all patients, median (quartile 1, quartile 3)	< .001	3 (1, 6.5)	3 (1, 6)	3 (0, 9.5)	1 (0, 4)	1 (0, 4)	< .001	C, E, F
Unknown, n		6	13	13	115	147
No. of days with bleeding of grade 2 or higher, within disease treatment category
Autologous or syngeneic stem cell transplantation, median (quartile 1, quartile 3)		4 (2, 7)	2 (1, 8)	2 (1, 8)	0 (0, 1)	1 (0, 2)	< .001	C, E, F
Unknown, n		3	1	2	31	37
Allogeneic stem cell transplantation, median (quartile 1, quartile 3)		3 (1, 6.5)	3.5 (1.5, 6)	5 (2, 17)	2 (0, 5)	2 (1, 6)	.002	E, F
Unknown, n		3	5	8	47	63
Chemotherapy without HSCT for hematologic malignancy, median (quartile 1, quartile 3)		1 (0, 3)	1 (0, 1)	0 (0, 3)	2 (0, 4)	2 (0, 4)	.30
Unknown, n		0	6	2	37	45
Chemotherapy without HSCT for solid tumor, median (quartile 1, quartile 3)		2 (0, 3)		0 (0, 0)		0 (0, 2)	.20
Unknown, n		0	1	1	0	2

^*A: 0-5 years vs 6-12 years; B: 0-5 years vs 13-18 years; C: 0-5 years vs ≥ 19 years; D: 6-12 years vs 13-18 years; E: 6-12 years vs ≥ 19 years; F: 13-18 years vs ≥ 19 years.